EGFR mutations in small-cell lung cancers in patients who have never smoked

摘要: To the Editor: Mutations in epidermal growth factor receptor gene (EGFR) occur 10 to 20 percent of non–small-cell lung cancers, specifically adenocarcinomas, and are associated with response EGFR tyrosine kinase inhibitors (erlotinib gefitinib).1 However, results screening small-cell cancers for mutations have been negative.2 Thus, not routinely tested mutations, nor they systematically evaluated responsiveness inhibitors. A 45-year-old woman who had never smoked masses right lung, pleura, mediastinum, frontal lobe was . . .